Concise review: Mesenchymal stem cell treatment of the complications of diabetes mellitus.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 21280154.
- Also identified by DOI 10.1002/stem.556 and PMC identifier 3059410.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Mesenchymal stem cells (MSCs) are multipotent, self-renewing cells that can be found in almost all postnatal organs and tissues. The main functional characteristics of MSCs are their immunomodulatory ability, capacity for self-renewal, and differentiation into mesodermal tissues. The ability of MSCs to differentiate into several cell types, including muscle, brain, vascular, skin, cartilage, and bone cells, makes them attractive as therapeutic agents for a number of diseases including complications of diabetes mellitus. We review here the potential of MSCs as new therapeutic agents in the treatment of diabetic cardiomyopathy, diabetic nephropathy, diabetic polyneuropathy, diabetic retinopathy, and diabetic wounds. Also, in this review we discuss the current limitations for MSCs therapy in humans.
Medical subject headings
- Diabetic Cardiomyopathies
- Diabetic Nephropathies
- Diabetic Neuropathies
- Diabetic Retinopathy
- Mesenchymal Stem Cell Transplantation
- Multipotent Stem Cells